bioAffinity Technologies (BIAF) Stock Analysis

What bioAffinity Technologies does

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

Key metrics

ETFs linked to BIAF

Broad-market and Healthcare sector ETFs an investor holding bioAffinity Technologies is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how BIAF fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for bioAffinity Technologies?

bioAffinity Technologies trades under the ticker BIAF on NASDAQ.

Which exchange is BIAF listed on?

BIAF is listed on NASDAQ.

What sector does bioAffinity Technologies operate in?

bioAffinity Technologies is classified in the Healthcare sector (Medical - Diagnostics & Research industry).

How can PortView help analyze BIAF in a portfolio?

PortView shows BIAF's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.